Literature DB >> 14576107

In vitro activity and interaction of clindamycin combined with dihydroartemisinin against Plasmodium falciparum.

M Ramharter1, H Noedl, H Winkler, W Graninger, W H Wernsdorfer, P G Kremsner, S Winkler.   

Abstract

Combination regimens are considered a valuable tool for the fight against drug-resistant falciparum malaria. This study was conducted to evaluate the antimalarial potential of clindamycin in combination with dihydroartemisinin in continuously cultured and in freshly isolated Plasmodium falciparum parasites, measuring the inhibition of Plasmodium falciparum histidine-rich protein II synthesis. Interaction analysis revealed a synergistic or additive mode of interaction at various concentration ratios in all continuously cultured parasites at the 50% effective concentration (EC(50)) level. Antagonism was not found for any of the culture-adapted parasites. In fresh P. falciparum isolates, a fixed clindamycin-dihydroartemisinin combination exhibited additive activity at the EC(50) and EC(90) levels. The drug mixture showed no significant activity correlation to other commonly used antimalarials. The clindamycin-dihydroartemisinin combination appears to be a promising candidate for clinical investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576107      PMCID: PMC253801          DOI: 10.1128/AAC.47.11.3494-3499.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Averting a malaria disaster.

Authors:  N J White; F Nosten; S Looareesuwan; W M Watkins; K Marsh; R W Snow; G Kokwaro; J Ouma; T T Hien; M E Molyneux; T E Taylor; C I Newbold; T K Ruebush; M Danis; B M Greenwood; R M Anderson; P Olliaro
Journal:  Lancet       Date:  1999-06-05       Impact factor: 79.321

2.  An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii.

Authors:  Manel Camps; Gustavo Arrizabalaga; John Boothroyd
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

3.  Antiplasmodial activity of halogenated lincomycin analogues in Plasmodium berghei-infected mice.

Authors:  C Lewis
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

4.  In vitro susceptibility of African Plasmodium falciparum isolates to dihydroartemisinin and the risk factors for resistance to qinghaosu.

Authors:  J Le Bras
Journal:  Med Trop (Mars)       Date:  1998

5.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

6.  The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice.

Authors:  A N Chawira; D C Warhurst; B L Robinson; W Peters
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

7.  Clindamycin activity against chloroquine-resistant Plasmodium falciparum.

Authors:  L S Seaberg; A R Parquette; I Y Gluzman; G W Phillips; T F Brodasky; D J Krogstad
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

8.  Malaria epidemiology in the province of Moyen Ogoov, Gabon.

Authors:  E Wildling; S Winkler; P G Kremsner; C Brandts; L Jenne; W H Wernsdorfer
Journal:  Trop Med Parasitol       Date:  1995-06

9.  [In vitro development of sodium artesunate resistance in Plasmodium falciparum].

Authors:  G F Jiang
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  1992

10.  Atovaquone and proguanil for Plasmodium falciparum malaria.

Authors:  P D Radloff; J Philipps; M Nkeyi; D Hutchinson; P G Kremsner
Journal:  Lancet       Date:  1996-06-01       Impact factor: 79.321

View more
  7 in total

1.  Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.

Authors:  P Starzengruber; K Thriemer; R Haque; W A Khan; H P Fuehrer; A Siedl; V Hofecker; B Ley; W H Wernsdorfer; H Noedl
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

2.  Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon.

Authors:  Ghyslain Mombo-Ngoma; Christian Kleine; Arti Basra; Heike Würbel; Daisy A Diop; Mesküre Capan; Ayola A Adegnika; Florian Kurth; Benjamin Mordmüller; Fanny Joanny; Peter G Kremsner; Michael Ramharter; Sabine Bélard
Journal:  Malar J       Date:  2012-07-10       Impact factor: 2.979

3.  In vitro activity of immunosuppressive drugs against Plasmodium falciparum.

Authors:  Luzia Veletzky; Khalid Rehman; Tilman Lingscheid; Wolfgang Poeppl; Felix Loetsch; Heinz Burgmann; Michael Ramharter
Journal:  Malar J       Date:  2014-12-04       Impact factor: 2.979

4.  Anti-bacterial activity of intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, mefloquine, and azithromycin.

Authors:  Mesküre Capan; Ghyslain Mombo-Ngoma; Athanasios Makristathis; Michael Ramharter
Journal:  Malar J       Date:  2010-10-29       Impact factor: 2.979

5.  Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: a retrospective cohort study.

Authors:  Lorenz Auer-Hackenberg; Thomas Staudinger; Andja Bojic; Gottfried Locker; Gerda C Leitner; Wolfgang Graninger; Stefan Winkler; Michael Ramharter; Nina Worel
Journal:  Malar J       Date:  2012-05-07       Impact factor: 2.979

6.  Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates.

Authors:  Peter Starzengruber; Hans-Peter Fuehrer; Paul Swoboda; Deepa Ganesh; Rashidul Haque; Wasif A Khan; Wolfgang Graninger; Harald Noedl
Journal:  Malar J       Date:  2014-06-10       Impact factor: 2.979

7.  Effect of mild medical hypothermia on in vitro growth of Plasmodium falciparum and the activity of anti-malarial drugs.

Authors:  Khalid Rehman; Ulrich Sauerzopf; Luzia Veletzky; Felix Lötsch; Mirjam Groger; Michael Ramharter
Journal:  Malar J       Date:  2016-03-15       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.